A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England
Ahmed Elsada
◽
Amy Zalin‐Miller
◽
Craig Knott
◽
Leonidas Caravotas
A. Tamas
◽
B. Németh
◽
N. Erler
◽
M. Csanádi
◽
T. Bacon
2017 ◽
Vol 17
◽
pp. S146-S148
2020 ◽
Vol 7
(5)
◽
pp. e354-e355
Terri Lynn Shigle
◽
Qaiser Bashir
2019 ◽
Vol 33
(9)
◽
pp. 2266-2275
◽
Ujjawal H. Gandhi
◽
Robert F. Cornell
◽
Arjun Lakshman
◽
Zhubin J. Gahvari
◽
Elizabeth McGehee
◽
...
2008 ◽
Vol 141
(2)
◽
pp. 135-148
◽
Prashant Kapoor
◽
Patricia T. Greipp
◽
William G. Morice
◽
S. Vincent Rajkumar
◽
Thomas E. Witzig
◽
...
2017 ◽
Vol 31
(5)
◽
pp. 1039-1047
◽
C Touzeau
◽
P Moreau
◽
C Dumontet
2012 ◽
Vol 30
(16)
◽
pp. 2013-2015
◽
Don M. Benson
◽
John C. Byrd
2016 ◽
Vol 52
(10)
◽
pp. 551
◽
C. Xia
◽
M. Ribeiro
◽
S. Scott
◽
S. Lonial
2018 ◽
Vol 18
◽
pp. S256-S257
Stephanie Hoffman
◽
Malathi Kandarpa
◽
Jing Christine Ye
Close
Export Citation Format
Close
Share Document
Close